SAN FRANCISCO, Nov. 21, 2017 -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announced that Scott D. Flora has been appointed to its Board of Directors, effective November 21, 2017. Mr. Flora, who brings more than 30 years of medical device leadership experience, has served as a senior advisor for Invuity since February 2015.
“We are thrilled to have Scott join our board and we hope to further leverage his extensive sales and marketing background and medical device domain expertise as we continue to broaden our commercial offerings,” said Invuity Chief Executive Officer Philip Sawyer.
Over the last several decades, Mr. Flora has built a history of successfully executing new product launches and commercial expansion, as well as driving business development efforts. Mr. Flora served as President, Global Business Unit, Surgical Devices at Covidien for five years. Before that he developed and mentored strong commercial teams over 20 years at Smith & Nephew, where he served in various positions, cumulating in his role as President & General Manager, Orthopedics Reconstruction. Mr. Flora’s was most recently the CEO of OmniGuide Surgical, where he led the $25 million venture-backed surgical energy business for three years. In addition, Mr. Flora serves and has served on numerous medical device company boards, including MAKO Surgical, Conventus Orthopedics and Agnovos Healthcare.
About Invuity®
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's patented Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women's health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
CONTACT:
Company Contact:
Jim Mackaness
Chief Financial Officer
Invuity, Inc.
415-655-2129
Investors:
Mark Klausner
Westwicke Partners
443-213-0501
[email protected]


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Washington Post Publisher Will Lewis Steps Down After Layoffs
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



